Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Corvus Pharmaceuticals (NASDAQ: CRVS) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, a virtual event. The clinical-stage biopharmaceutical company's leadership team will deliver a corporate overview presentation on Tuesday, February 11, 2025, at 9:20 am ET.
The company will also conduct one-on-one meetings with investors during the conference. A webcast of the presentation will be accessible through the investor relations section of Corvus's website, with availability both live and for 90 days following the event.
Corvus Pharmaceuticals (NASDAQ: CRVS) ha annunciato la sua partecipazione alla 35a Conferenza Annuale Oppenheimer sulle Scienze della Salute, un evento virtuale. Il team di leadership della compagnia biofarmaceutica in fase clinica presenterà una panoramica aziendale martedì 11 febbraio 2025, alle 9:20 ET.
L'azienda condurrà anche incontri individuali con gli investitori durante la conferenza. Un webcast della presentazione sarà accessibile attraverso la sezione delle relazioni con gli investitori del sito web di Corvus, con disponibilità sia in diretta che per 90 giorni dopo l'evento.
Corvus Pharmaceuticals (NASDAQ: CRVS) ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer, un evento virtual. El equipo de liderazgo de la compañía biofarmacéutica en etapa clínica ofrecerá una presentación sobre la empresa el martes 11 de febrero de 2025, a las 9:20 am ET.
La empresa también llevará a cabo reuniones individuales con inversores durante la conferencia. Una retransmisión de la presentación estará disponible a través de la sección de relaciones con inversores del sitio web de Corvus, con acceso tanto en vivo como durante 90 días después del evento.
코르부스 제약회사 (NASDAQ: CRVS)는 오펜하이머 제35회 연례 건강 과학 컨퍼런스에 참여한다고 발표했습니다. 임상 단계의 생명공학 회사의 리더십 팀은 2025년 2월 11일 화요일, 오전 9시 20분 ET에 기업 개요 발표를 진행할 예정입니다.
회사는 컨퍼런스 기간 동안 투자자와 1대1 미팅도 실시할 것입니다. 발표의 웹캐스트는 코르부스 웹사이트 투자자 관계 섹션을 통해 접근할 수 있으며, 생중계와 이벤트 후 90일 동안 이용 가능합니다.
Corvus Pharmaceuticals (NASDAQ: CRVS) a annoncé sa participation à la 35e Conférence Annuelle Oppenheimer sur les Sciences de la Santé, un événement virtuel. L'équipe dirigeante de l'entreprise biopharmaceutique en phase clinique fera une présentation sur l'entreprise mardi 11 février 2025, à 9h20 ET.
L'entreprise organisera également des réunions individuelles avec des investisseurs durant la conférence. Un webcast de la présentation sera accessible via la section des relations investisseur du site Web de Corvus, avec une disponibilité à la fois en direct et pendant 90 jours après l'événement.
Corvus Pharmaceuticals (NASDAQ: CRVS) hat seine Teilnahme an der 35. jährlichen Oppenheimer-Konferenz über Gesundheitswissenschaften angekündigt, einem virtuellen Event. Das Führungsteam des klinischen Biopharmaunternehmens wird am Dienstag, 11. Februar 2025, um 9:20 Uhr ET eine Unternehmensübersicht präsentieren.
Das Unternehmen wird während der Konferenz auch Einzelgespräche mit Anlegern führen. Ein Webcast der Präsentation wird über den Bereich Investor Relations der Website von Corvus zugänglich sein, sowohl live als auch für 90 Tage nach der Veranstaltung.
- None.
- None.
BURLINGAME, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is being held virtually. The presentation will be on Tuesday, February 11, 2025 at 9:20 am ET.
A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
When is Corvus Pharmaceuticals (CRVS) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors access the CRVS Oppenheimer Conference presentation?
What type of meetings will CRVS conduct at the Oppenheimer Healthcare Conference?
Is the Oppenheimer Healthcare Conference 2025 where CRVS is presenting an in-person event?
